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Background
No biomarker has been validated so far to predict the
need for adjuvant chemotherapy in Stage II colon cancer
(CC), and current guidelines, e.g. NCCN, only rely on
the identification of high-risk features such as MSI,
pathological tumor characteristics or expected che-
motherapy efficacy/safety ratio in each individual
patient. In contrast, adjuvant chemotherapy is recom-
mended for all Stage III colon cancer (CC). The Immu-
noscore® (IS®), based on CD3- and CD8-positive cell
quantification using a digital pathology automated analy-
sis, has been shown to be a strong prognostic indicator in
CC, surpassing the TNM classification [1]. We explore
here the potential of the Immunoscore® to predict the
need for 5-FU adjuvant chemotherapy in Stage II and in
Stage III CC.
Methods
The IS® was calculated as previously described on a ret-
rospective cohort of 456 colorectal cancer patients from
Hôpital Européen Georges Pompidou, who underwent
primary tumor resection between 1990 and 2003. For
the analysis of chemotherapy benefit on disease-free sur-
vival, patients were grouped in 3 subcohorts based on
their IS®: IS® 0-1 (worst prognosis), IS® 2-3 (intermedi-
ate prognosis) and IS® 4 (best prognosis).
Results
Stage II and Stage III cases represent resp. 327 (71.7%) and
129 (28.3%) of the cohort. 5-FU adjuvant chemotherapy
was administered to 13.8% and 60.5% of Stage II and Stage
III CC resp. IS® 0-1, IS® 2-3 and IS® 4 represented 11.6%,
35.2% and 53.2% in the Stage II population, and 18.6%,
36.4% and 45% of patients in the Stage III population. Dis-
ease-free survival of IS® 2-3 patients was improved by
administration of 5-FU chemotherapy (Stage III: HR=2.69
(1.02-7.11) pV = 0.038, and Stage II: HR=1.47 (0.35-6.18)
pV not reaching significance). IS® 4 patients had the best
and IS® 0-1 patients the worst outcome in both Stage II
and Stage III populations. There was no statistically signif-
icant benefit of chemotherapy on disease-free survival for
IS® 4 or IS® 0-1 patients in both Stage II and Stage III
populations.
Conclusion
IS®, which has been developed to be an easy-to-use rou-
tine practice biomarker, may represent a valid biomarker
to precisely identify stage II and stage III CC patients most
likely to benefit from 5-FU chemotherapy. These results,
based on a single center retrospective cohort, warrant
further validation on a larger, clinical trial, cohort.
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